Compass Therapeutics' (CMPX) "Sell (D-)" Rating Reiterated at Weiss Ratings

Key Points

• Compass Therapeutics had its "sell (D-)" rating reaffirmed by Weiss Ratings, reflecting ongoing concerns about the company's stock performance.
• Despite the negative rating from Weiss, several other analysts have issued more positive assessments, with ratings ranging from "buy" to "outperform" and price targets up to $32.00.
• The company's stock is currently trading at $3.90, having a market capitalization of approximately $539.29 million, amidst varying institutional investments.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities researchers at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

Several other analysts also recently commented on CMPX. Raymond James Financial raised Compass Therapeutics to an "outperform" rating and set a $9.00 price objective for the company in a research note on Tuesday, July 1st. Compass Point set a $10.00 target price on Compass Therapeutics in a report on Monday. D. Boral Capital reaffirmed a "buy" rating and issued a $32.00 target price on shares of Compass Therapeutics in a report on Tuesday, August 12th. Guggenheim upped their target price on Compass Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a report on Tuesday, August 12th. Finally, Lifesci Capital started coverage on Compass Therapeutics in a report on Monday. They issued an "outperform" rating and a $10.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $13.10.

Compass Therapeutics Stock Performance

Shares of Compass Therapeutics stock traded up $0.29 on Wednesday, hitting $3.90. The company had a trading volume of 1,779,880 shares, compared to its average volume of 1,761,406. The stock has a market capitalization of $539.29 million, a price-to-earnings ratio of -8.67 and a beta of 1.48. Compass Therapeutics has a 1 year low of $1.27 and a 1 year high of $4.08. The stock has a 50 day moving average of $3.31 and a 200-day moving average of $2.62.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01). Equities analysts anticipate that Compass Therapeutics will post -0.36 earnings per share for the current year.

Institutional Investors Weigh In On Compass Therapeutics

Several institutional investors have recently made changes to their positions in CMPX. Bank of America Corp DE lifted its position in shares of Compass Therapeutics by 36.6% during the fourth quarter. Bank of America Corp DE now owns 113,020 shares of the company's stock worth $164,000 after acquiring an additional 30,303 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in shares of Compass Therapeutics during the fourth quarter worth $35,000. Simplicity Wealth LLC purchased a new stake in shares of Compass Therapeutics during the first quarter worth $88,000. SG Americas Securities LLC lifted its position in shares of Compass Therapeutics by 138.2% during the first quarter. SG Americas Securities LLC now owns 940,784 shares of the company's stock worth $1,787,000 after acquiring an additional 545,767 shares in the last quarter. Finally, Vontobel Holding Ltd. purchased a new stake in shares of Compass Therapeutics during the first quarter worth $57,000. Hedge funds and other institutional investors own 68.43% of the company's stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.